ARCHIVE

• New Therapeutic GL for Arteriosclerotic Diseases Published
  August 19, 2002

• ACNielsen, So-net M3 to Start Market Survey Service via MR-kun
  August 19, 2002

• Shionogi to Collaborate with Oncotherapy Science for Genome-based Drug Discovery
  August 19, 2002

• Chronic Heart Failure as Additional Indication Approved for Daiichi's Carvedilol
  August 19, 2002

• Nippon Kayaku Developing DDS for Anticancer Drugs
  August 19, 2002

• Prulifloxacin Recommended for Approval
  August 5, 2002

• Pharmaco-business Innovation Chair to Be Established at Univ. of Tokyo
  August 5, 2002

• Views of the JPMA President Regarding the Amendment of the Pharmaceutical Affairs Law
  August 5, 2002

• Dear-Doctor Letter Issued for Ticlopidine
  August 5, 2002

• Risk Management, Cost-effectiveness Analysis Stressed: CMIC Seminar
  August 5, 2002

• Council Insists on Entry of Private Corporations into Medical Facilities
  August 5, 2002

• Serious ADRs Reported for 3 Products Including Edaravone
  August 5, 2002

• Novartis to Offer Research Grants for Cancer, Diabetes
  August 5, 2002

• Japan, EU to Start Drug GMP Mutual Recognition around July 2003
  August 5, 2002

• REGULATORY NEWS IN BRIEF
  August 5, 2002

• OTS NEWS IN BRIEF
  August 5, 2002

• Korosho to Strictly Crack Down on Suspicious Health Foods
  August 5, 2002

• MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
  August 5, 2002

• Olympus: New Version of EndoALPHA
  August 5, 2002

• Eisai to Promote Pfizer's Cerebyx in US
  August 5, 2002

ページ

• « 先頭
• ‹ Prev
• …
• 659
• 660
• 661
• 662
• 663
• 664
• 665
• 666
• 667
• …
• Next ›
• 最終 »